BioLabs Reports Q2 Revenue Growth; OneTest Cancer Revenue Climbs 47%
20/20 BioLabs (AIDX) reported Q2 2026 revenue up 36.5% to $0.7M. OneTest revenue rose 47.1% to $0.7M and was 95.3% of total revenue. Gross margin increased to 41.7% from 30.5%. Operating expenses rose to $1.5M; net loss widened to $1.5M ($0.26/share). Cash was $4.5M at June 30, 2026.
How this was made
The 30-second read
Why it matters
Q2 results provide fresh evidence of OneTest revenue momentum and improved gross margin, alongside higher operating costs and a wider net loss. The company also highlights expanding state-funded firefighter screening and new account wins, which may influence near-term sentiment and forward revenue expectations.
Market read
Traders get a new quarterly datapoint on revenue growth, gross margin expansion, and commercial scaling signals (state programs, new accounts, and new channel pilots).
What to watch
Cash is $4.5M at June 30, 2026 and net loss widened; traders may need to monitor burn rate and whether firefighter program scaling translates into sustained commercial orders beyond pilots.
Background
BioLabs sells laboratory-based blood tests under the OneTest brand, including OneTest for Cancer (MCED) and OneTest for Longevity.
Ticker impact
BioLabs reported Q2 2026 results, with OneTest for Cancer revenue up 47% YoY and gross margin expanding to 41.7%.
Near-term bias modestly positive on the revenue and gross margin beats, tempered by the larger net loss and ongoing cash burn.
Revenue growth and gross margin expansion are concrete positives, while operating expense growth and a wider net loss (including non-cash charges) limit upside conviction. The article also flags testing volume as the key driver for the rest of 2026, which can support follow-through if volumes track expectations.
Market effects
Adds incremental datapoints on commercial traction and margin profile for early cancer blood-test commercialization.
No clear regional market spillover beyond US state program adoption mentioned.
Primarily US-focused commercialization and procurement; limited global read-through.
Counterpoint
Gross margin improvement may be partly volume-driven and could reverse if testing volumes slow, especially with operating expenses rising.
Key entities
- companyBioLabs, Inc.
Reported Q2 2026 results and provided commercial and balance-sheet updates tied to OneTest testing volumes.
- productOneTest for Cancer
Multi-cancer early detection blood test; revenue rose 47.1% YoY in Q2 and drove most total revenue.
- partnerGiant Food
Launched a three-month retail pilot for OneTest for Longevity through participating stores.
